Baillie Gifford & Co. raised its position in Aduro Biotech, Inc. (NASDAQ:ADRO) by 45.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 422,700 shares of the biotechnology company’s stock after purchasing an additional 132,700 shares during the quarter. Baillie Gifford & Co. owned 0.57% of Aduro Biotech worth $4,819,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ADRO. Legal & General Group Plc raised its stake in shares of Aduro Biotech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 2,119 shares during the period. Tudor Investment Corp ET AL raised its stake in shares of Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,984 shares during the period. American International Group Inc. raised its stake in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 1,447 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Aduro Biotech in the 2nd quarter valued at about $353,000. 35.05% of the stock is currently owned by hedge funds and other institutional investors.
In related news, COO Gregory W. Schafer sold 20,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $11.70, for a total value of $234,000.00. Following the sale, the chief operating officer now owns 131,645 shares in the company, valued at approximately $1,540,246.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas W. Dubensky sold 50,000 shares of the company’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $11.33, for a total transaction of $566,500.00. Following the completion of the sale, the insider now owns 51,700 shares in the company, valued at approximately $585,761. The disclosure for this sale can be found here. Insiders sold a total of 453,923 shares of company stock worth $5,212,846 in the last 90 days. 6.60% of the stock is currently owned by company insiders.
Several analysts have issued reports on ADRO shares. HC Wainwright set a $18.00 price target on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. BidaskClub downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company started coverage on Aduro Biotech in a research note on Tuesday, July 18th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $19.00.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2886553/baillie-gifford-co-purchases-132700-shares-of-aduro-biotech-inc-adro.html.
Shares of Aduro Biotech, Inc. (ADRO) opened at 11.15 on Tuesday. Aduro Biotech, Inc. has a 52-week low of $8.75 and a 52-week high of $15.52. The company has a 50 day moving average price of $11.98 and a 200-day moving average price of $10.98. The firm’s market cap is $831.92 million.
Aduro Biotech (NASDAQ:ADRO) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. During the same quarter in the prior year, the company earned $0.03 EPS. The company’s revenue was down 84.9% on a year-over-year basis. On average, analysts expect that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current fiscal year.
Aduro Biotech Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech, Inc. (NASDAQ:ADRO).
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.